What is a stock summary page? Click here for an overview.
Business Description
Durect Corp
NAICS : 325412
SIC : 2834
ISIN : US2666051048
Compare
Compare
Traded in other countries / regions
DRRX.USADC8A.Germany Index Membership
Russell 2000 IPO Date
2000-09-28Description
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.35 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -46.85 | |||||
| Beneish M-Score | 0.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.6 | |||||
| 3-Year EBITDA Growth Rate | 26 | |||||
| 3-Year EPS without NRI Growth Rate | 28.4 | |||||
| 3-Year FCF Growth Rate | 28.2 | |||||
| 3-Year Book Growth Rate | -51.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 207.76 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.14 | |||||
| 9-Day RSI | 49.86 | |||||
| 14-Day RSI | 46.88 | |||||
| 3-1 Month Momentum % | -0.12 | |||||
| 6-1 Month Momentum % | -38.1 | |||||
| 12-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.7 | |||||
| Cash Ratio | 1.53 | |||||
| Days Inventory | 7006.13 | |||||
| Days Sales Outstanding | 148.05 | |||||
| Days Payable | 3468.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.9 | |||||
| Shareholder Yield % | 43.73 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.16 | |||||
| Operating Margin % | -931.17 | |||||
| Net Margin % | -409.85 | |||||
| FCF Margin % | -939.73 | |||||
| ROE % | -108.19 | |||||
| ROA % | -27.08 | |||||
| ROIC % | -76.42 | |||||
| 3-Year ROIIC % | -161.44 | |||||
| ROC (Joel Greenblatt) % | -602.95 | |||||
| ROCE % | -181.55 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.79 | |||||
| PB Ratio | 2.26 | |||||
| Price-to-Tangible-Book | 3.12 | |||||
| EV-to-EBIT | -0.57 | |||||
| EV-to-EBITDA | -0.57 | |||||
| EV-to-Revenue | 5.28 | |||||
| EV-to-Forward-Revenue | 27.15 | |||||
| EV-to-FCF | -0.57 | |||||
| Price-to-GF-Value | 1.31 | |||||
| Price-to-Median-PS-Value | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 5.04 | |||||
| Price-to-Net-Cash | 8.2 | |||||
| Earnings Yield (Greenblatt) % | -175.44 | |||||
| FCF Yield % | -93.77 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers